Pharmaceuticals
Gene Solutions and NEWCL Forge Strategic Partnership to Advance Genetic Testing in Taiwan
NEW TAIPEI CITY, May 16, 2025 /PRNewswire/ -- In a groundbreaking move, Gene
Solutions
2025-05-16 19:06
4010
Nordic Bioscience launches novel Endotrophin assay
HERLEV, Denmark, May 16, 2025 /PRNewswire/ -- Nordic Bioscience introduces nordicEndotrophin™, a fully automated high-precision assay that selectively quantifies the intact 77-amino-acid Endotrophin signaling hormone—qualified in the CAP/CLIA certified Nordic Bioscience laboratory. When integrate...
2025-05-16 14:30
2996
ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF)
SHANGHAI, May 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic pulmonary fibrosis (IPF). The study, led by Professor Huaping Dai of the Departmen...
2025-05-16 09:00
5123
Second Head-to-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver Disease (GLORY-3)
SAN FRANCISCO and SUZHOU, China, May 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic...
2025-05-16 08:00
8628
STEERLife Redefines Potent Drug Development with Clean, Green, Continuous Processing
As a next-gen CRDMO, driving global pharma with continuous, solvent-free tech for potent drug development BENGALURU, India, May 15, 2025 /PRNewswire/ -- STEERLife, the life sciences division of STEER World, is advancing the development and manufacturing of potent and complex drug products. This...
2025-05-15 20:07
2200
STEERLife Redefines Potent Drug Development with Clean, Green, Continuous Processing
As a next-gen CRDMO, driving global pharma with continuous, solvent-free tech for potent drug development BENGALURU, India, May 15, 2025 /PRNewswire/ -- STEERLife, the life sciences division of STEER World, is advancing the development and manufacturing of potent and complex drug products. This...
2025-05-15 11:30
2951
Clarivate Enhances OFF-X with Pathway Maps to Accelerate Target Safety Assessments
R&D teams can streamline safety evaluations, reduce risks and enable faster decision-making in drug development using new visual and data-driven insights LONDON, May 14, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the ...
2025-05-14 16:00
2601
Caliway Announces Successful EOP2 Meeting with the FDA for CBL-514 in Reduction of Abdominal Subcutaneous Fat
- Caliway has completed the End-of-Phase 2 (EOP2) meeting with the U.S. FDA for CBL-514, the world's first investigational drug for large-area subcutaneous fat reduction developed under the 505(b)(1) regulatory pathway. - The company has received the EOP2 meeting minutes, confirming the ...
2025-05-14 12:01
3876
Dupixent approved in Singapore as the first-ever biologic medicine for patients with COPD
* Following recent approvals in the EU, US and China, the Singapore approval is based on two replicate phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placebo. SING...
2025-05-14 10:30
2837
Novo Holdings Announces Investment in SCHOTT Poonawalla to Accelerate Growth and Innovation in Injectable Drug Packaging
SINGAPORE, May 14, 2025 /PRNewswire/ -- Novo Holdings, a global life sciences investor, today announced its investment in SCHOTT Poonawalla,India's leading provider of high-quality drug containment and delivery solutions for injectable pharmaceuticals, alongside TPG Growth, the middle market and ...
2025-05-14 09:00
3308
Rockwell Automation Launches PharmaSuite 12.00 to Accelerate Secure, Scalable Deployments
Latest MES release helps pharmaceutical and biopharmaceutical manufacturers
simplify system management, improve flexibility and speed time-to-value
MILWAUKEE, May 13, 2025 /PRNewswire/ -- Rockwell Automation, Inc.
2025-05-13 19:00
3382
Eligo Bioscience Awarded $5 Million to Advance Breakthrough Genetic Medicine Platform for Immuno-Dermatology
* Funding is part of the call for proposals "Innovations in Biotherapies and Bioproduction," coordinated by the Health Innovation Agency under France 2030 strategy, operated on behalf of the French government by Bpifrance PARIS, May 13, 2025 /PRNewswire/ -- Eligo Bioscience, a biotechnology com...
2025-05-13 17:00
3436
Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congress
SHANGHAI, May 13, 2025 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (02256.HK) today announced that updated results from the phase 2 study of irpagratinib (ABSK011) in combination with atezolizumab for the treatment of advanced hepatocellular carcinoma (HCC) will be presented at the 2025 ESMO G...
2025-05-13 11:38
6818
Illuccix China Phase 3 Study Completes Enrolment
MELBOURNE, Australia and INDIANAPOLIS, May 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that the pivotal Phase 3 registration study of TLX591-CDx (Illuccix®, Kit for the preparation of68Ga-PSMA-11) for prostate cancer imagi...
2025-05-13 07:22
2848
Poised to Reshape Treatment Landscape: The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS
YANTAI, China, May 12, 2025 /PRNewswire/ -- On May 12th, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that its phase 3 clinical trial (Study ID: RC48-C016) on disitamab vedotin (DV, brand name: 爱地希® ), the first domestically approved antibody-drug conjugate (ADC...
2025-05-12 16:29
5872
Prof. Mike Chan's Precision Medicine Vision Validated by Landmark Human Cytology Study Mapping Over 400 Distinct Cell Types - with Special Focus on the Brain
HEIDELBERG, Germany, May 12, 2025 /PRNewswire/ -- A groundbreaking international study has mapped over 400 distinct human cell types, providing powerful validation for Prof.Mike Chan's longstanding vision of organ-specific, cell-specific regenerative medicine. This pivotal research[1], authored b...
2025-05-12 15:44
5493
Colorcon and ASHA Cellulose Announce New Partnership to Support the Development & Manufacture of Barrier Membrane Formulations for the Pharmaceutical and Nutraceutical Industries
HARLEYSVILLE, Pa. and MUMBAI, India, May 8, 2025 /PRNewswire/ -- Colorcon, a global leader of film coating systems, specialty excipients, controlled release formulations and controlled atmosphere packaging for the healthcare industry, today announced an exclusive partnership with ASHA Cellulose, ...
2025-05-08 17:00
3050
SCG Announces Late-Breaking Clinical Data of SCG101 in HBV-Related Hepatocellular Carcinoma Presented at EASL 2025
SINGAPORE, May 8, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from its Phase 1 trial evaluating SCG101, autologous HBV-specific...
2025-05-08 09:00
3103
Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss
* End of treatment (EOT) data from Cohort 4 of the ENSURE study suggest that patients responding to prior BRII-179 treatment achieved faster and higher rate of surface antigen clearance with curative treatments compared to BRII-179naïve participants, strengthening the case for a novel enrichmen...
2025-05-08 08:10
4547
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
MELBOURNE, Australia and INDIANAPOLIS, May 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published inThyroid, the official journal of the ...
2025-05-08 05:00
3057
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 320 media titles]
2026-09-03 23:53
TEATER BESAR TAMAN ISMAIL MARZUKI SIMPLIFIES WIRELESS WORKFLOWS WITH SENNHEISER SPECTERA
[Picked up by 283 media titles]
2026-09-03 10:00
A Taste of Thailand: Discover the Spirit of the Elephant at Chang Thai
[Picked up by 282 media titles]
2026-09-03 10:00
From Micro-Weddings to Milestones: Celebrating Life's Special Moments at Four Seasons Resorts of Asia
[Picked up by 282 media titles]
2026-09-04 10:43
OGA 2026 OPENS WITH STRONGER FOCUS ON MARKET ACCESS, REGIONAL PROJECTS AND ENERGY OPPORTUNITIES
[Picked up by 276 media titles]
2026-09-04 01:35
Most Read
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
2026-09-02 12:17
12552
